In PTEN wild-type prostate cancer cells, NRG1 stimulation conferred resistance to AR-targeted therapy with enzalutamide, whereas in PTEN knock-out cells, NRG1 paradoxically inhibited growth and its blockade had no effect [22,43]. The gene discussed is PTEN; the disease is prostate cancer.